Neurocrine Biosciences announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117570 in healthy adult participants. NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist that may have the potential to treat neurological and neuropsychiatric conditions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Neurocrine’s Ingrezza shows improvement in tardive dyskinesia study
- Neurocrine presents new INGREZZA capsules data
- Biotech Alert: Searches spiking for these stocks today
- Neurocrine Stock (NASDAQ:NBIX): Investors and Analysts are Bullish
- Neurocrine price target raised to $123 at Jefferies after Ingrezza HD approval